What happens when landmark trials challenge long-standing surgical standards?In this episode of Doc to Doc, Dr. Thomas Morrissey, director of gynecologic oncology at Lynn Cancer Institute, joins Dr. Ryan Kahn, gynecologic oncologist at Miami Cancer Institute, to explore how data from pivotal studies like TRUST, SHAPE, and MIRASOL are redefining treatment decisions in gynecologic cancer.From respectability scoring to the evolving role of checkpoint inhibitors and targeted antibody-drug conjugates, this conversation highlights a bold shift toward more personalized, evidence-based care, and what every clinician should know in this new era.Thomas Morrissey, M.D., Director of Gynecologic Oncology with the Eugene M. & Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital. Ryan Kahn, M.D.Gynecologic OncologistBaptist Health Miami Cancer Institute

Ver todos los episodios